UK Agency Tests Remote Inspections Program To Identify At-Risk GDP Sites
Executive Summary
The UK Medicines and Healthcare products Regulatory Agency is testing a new remote, office-based inspection process, in place of physical inspections, to assess risk at “satellite sites” that perform a limited number of good distribution practice-related activities for companies.
You may also be interested in...
COVID-19: UK MHRA Says Non-Essential Inspections Will Be Office-Based
The UK’s Medicines and Healthcare products Regulatory Agency is replacing all non-essential on-site inspections with office-based assessments due to the coronavirus pandemic. The agency also plans to rely on information from international regulatory partners to maintain oversight.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.